Towards Healthcare
Huntington's Disease Treatment Market Uplifts $1409.15 Mn by 2034

Huntington's Disease Treatment Market Advances in Neuroprotective Strategies

According to market projections, the huntington's disease treatment sector is expected to grow from USD 664.9 million in 2024 to USD 1409.15 million by 2034, reflecting a CAGR of 7.8%. Huntington's disease treatment focuses on managing symptoms, as there's no cure yet. Medications help control movement issues and mood changes, while therapy supports speech, mobility, and mental health. Lifestyle changes, like regular exercise and a balanced diet, can improve well-being. Research on new treatments is ongoing.

Content

Introduction

  • Research Objective
  • Scope of the Study
  • Definition and Taxonomy

Research Methodology

  • Research Approach
  • Data Sources
  • Assumptions

Executive Summary

  • Synopsis
  • Analyst Recommendations

Market Overview 

  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Value Chain Analysis
    • Raw Material Sourcing
    • Manufacturing Process
    • Logistics & Transportation
    • Buyer Preferences
  • Trends
    • Market Trends
    • Technological Trends
  • Porter’s Five Forces Analysis
    • Bargaining Power of Suppliers
    • Bargaining Power of Buyers
    • Threat of Substitute
    • Threat of New Entrants
    • Degree of Competition
  • PESTLE Analysis for 5 Leading Countries
    • Regulatory Framework for Leading Countries/Regions
    • Supply Demand Analysis
    • Production & Consumption Statistics
    • Export Import Statistics
    • Price Trend Analysis

Global Huntington's Disease Treatment Market Assessment

  • Overview
  • Global Huntington's Disease Treatment Market Size Value (US$) and Volume (Million Tons), by Diagnosis Type (2021 – 2033)
    • Diagnostic Imaging
    • Genetic Testing
    • Others
  • Global Huntington's Disease Treatment Market Size Value (US$) and Volume (Million Tons), by Drug Type (2021 – 2033)
    • Tetrabenazine
    • Deutetrabenazine
    • Other Drugs
  • Global Huntington's Disease Treatment Market Size Value (US$) and Volume (Million Tons), by Treatment Type (2021 – 2033)
    • Symptomatic Therapy
    • Disease-Modifying Therapy
    • Others
  • Global Huntington's Disease Treatment Market Size Value (US$) and Volume (Million Tons), by Geography (2021 – 2033)
    • North America
    • Europe
    • Asia-Pacific
    • Latin America
    • The Middle East and Africa

North America Huntington's Disease Treatment Market Assessment

  • Overview
  • North America Huntington's Disease Treatment Market Size Value (US$) and Volume (Million Tons), by Diagnosis Type (2021 – 2033)
    • Diagnostic Imaging
    • Genetic Testing
    • Others
  • North America Huntington's Disease Treatment Market Size Value (US$) and Volume (Million Tons), by Drug Type (2021 – 2033)
    • Tetrabenazine
    • Deutetrabenazine
    • Other Drugs
  • North America Huntington's Disease Treatment Market Size Value (US$) and Volume (Million Tons), by Treatment Type (2021 – 2033)
    • Symptomatic Therapy
    • Disease-Modifying Therapy
    • Others

Europe Huntington's Disease Treatment Market Assessment

  • Overview
  • Europe Huntington's Disease Treatment Market Size Value (US$) and Volume (Million Tons), by Diagnosis Type (2021 – 2033)
    • Diagnostic Imaging
    • Genetic Testing
    • Others
  • Europe Huntington's Disease Treatment Market Size Value (US$) and Volume (Million Tons), by Drug Type (2021 – 2033)
    • Tetrabenazine
    • Deutetrabenazine
    • Other Drugs
  • Europe Huntington's Disease Treatment Market Size Value (US$) and Volume (Million Tons), by Treatment Type (2021 – 2033)
    • Symptomatic Therapy
    • Disease-Modifying Therapy
    • Others

Asia-Pacific Huntington's Disease Treatment Market Assessment

  • Overview
  • Asia-Pacific Huntington's Disease Treatment Market Size Value (US$) and Volume (Million Tons), by Diagnosis Type (2021 – 2033)
    • Diagnostic Imaging
    • Genetic Testing
    • Others
  • Asia-Pacific Huntington's Disease Treatment Market Size Value (US$) and Volume (Million Tons), by Drug Type (2021 – 2033)
    • Tetrabenazine
    • Deutetrabenazine
    • Other Drugs
  • Asia-Pacific Huntington's Disease Treatment Market Size Value (US$) and Volume (Million Tons), by Treatment Type (2021 – 2033)
    • Symptomatic Therapy
    • Disease-Modifying Therapy
    • Others

Latin America Huntington's Disease Treatment Market Assessment

  • Overview
  • Latin America Huntington's Disease Treatment Market Size Value (US$) and Volume (Million Tons), by Diagnosis Type (2021 – 2033)
    • Diagnostic Imaging
    • Genetic Testing
    • Others
  • Latin America Huntington's Disease Treatment Market Size Value (US$) and Volume (Million Tons), by Drug Type (2021 – 2033)
    • Tetrabenazine
    • Deutetrabenazine
    • Other Drugs
  • Latin America Huntington's Disease Treatment Market Size Value (US$) and Volume (Million Tons), by Treatment Type (2021 – 2033)
    • Symptomatic Therapy
    • Disease-Modifying Therapy
    • Others

The Middle East and Africa Huntington's Disease Treatment Market Assessment

  • Overview
  • The Middle East and Africa Huntington's Disease Treatment Market Size Value (US$) and Volume (Million Tons), by Diagnosis Type (2021 – 2033)
    • Diagnostic Imaging
    • Genetic Testing
    • Others
  • The Middle East and Africa Huntington's Disease Treatment Market Size Value (US$) and Volume (Million Tons), by Drug Type (2021 – 2033)
    • Tetrabenazine
    • Deutetrabenazine
    • Other Drugs
  • The Middle East and Africa Huntington's Disease Treatment Market Size Value (US$) and Volume (Million Tons), by Treatment Type (2021 – 2033)
    • Symptomatic Therapy
    • Disease-Modifying Therapy
    • Others

Company Profiles

  • Apitex Inc.
    • Company Overview
    • Geographic Footprints
    • Financial Performance
    • Product Portfolio
    • SWOT Analysis
    • R&D Efforts
    • Recent Developments & Strategic Collaborations
      • Product Launch/M&A/Technical Collaboration
  • Teva Pharmaceuticals Industries
  • Athena Diagnostic
  • Alnylam Pharmaceuticals
  • Elekta AB
  • Pfizer Inc.
  • SOM BIOTECH
  • Armata Pharmaceuticals, Inc.
  • H. Lundbeck A/S
  • Fulgent Genetics

Conclusion & Recommendations

  • Insight Code: 5100
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: May 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

Talk to us
FAQ's

Huntingtons disease (HD) is a neurodegenerative disorder with symptoms affecting both the body and mind. Manifesting in adulthood includes hallmark motor symptoms like involuntary dance-like movements (chorea) and cognitive challenges such as difficulty thinking and concentrating. Psychiatric symptoms like depression and anxiety, along with behavioral changes and cognitive decline, contribute to the complexity of HD. The condition is progressive, varying in the rate and severity of symptoms among individuals. Emotional and social challenges are shared, underscoring the importance of early diagnosis and comprehensive care for individuals and their families.

Current treatments focus on symptom management, including medications for chorea, depression, anxiety and mood swings. Physical, occupational and speech therapies help address motor and communication difficulties. Supportive care, including emotional and psychological support, is crucial for individuals and their families, often provided through support groups and counseling. Ongoing research involves clinical trials exploring potential disease-modifying therapies to alter HDs course. It is important to note that HD research and treatment may have advanced since then and consulting healthcare professionals for the latest information is recommended.

Prominent pharmaceutical and biotech companies worldwide, including those in the United States, Europe and Asia, actively participate in huntingtons disease research and treatment development. Clinical trials, research initiatives and advancements in therapeutic approaches are distributed globally.

World Health Organization, American Society of Huntingtons Disease, National Institute of Health, Food and Drug Administration, Center for Disease Control and Prevention.
Any Questions